Amphotericin B Clinical Studies
Liposomal Amphotericin B in outpatient parenteral antimicrobial therapy
Burnett YJ, Spec A, Ahmed MM, Powderly WG, Hamad Y. Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy. Antimicrobial agents and chemotherapy. 2021 May 18;65(6):e01876-20.
The Study concluded that outpatient treatment with Liposomal Amphotericin B is
Amphotericin B Clinical Studies
IDSA Guidelines for the management of invasive candidiasis: 2016 Update
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016 Feb 15;62(4):e1-50.
The guideline suggests that Lipid formulations of amphotericin B (AmB) (3–5 mg/kg daily) are reasonable alternatives in patients having intolerance, limited availability, or resistance to other antifungal agents. (strong recommendation; high-quality evidence).
Amphotericin B Clinical Studies
IDSA Guidelines for the management of invasive Aspergillosis: 2016 Update
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016 Feb 15;62(4):e1-50.
The guideline suggests that Amphotericin B (AmB) deoxycholate & its lipid formulations are ideal for initial and salvage therapy of Aspergillus infections when voriconazole cannot be administered. Amphotericin B (AmB) deoxycholate whould be reserved for resource limited settings & Lipid formulations of AmB should be preferred in these cases. (strong recommendation; moderate-quality evidence).
Amphotericin B Clinical Studies
IDSA Guidelines for the management of Cryptococcal Disease: 2010 Update
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical infectious diseases. 2010 Feb 1;50(3):291-322.
The guideline suggests that Amphotericin B (AmB) deoxycholate along with flucytosine should be considered as primary therapy for 2 weeks. Lipid formulations of Amphotericin B can be considered in patients with renal dysfuntion (liposomal AmB (3–4 mg/kg per day IV) and AmB lipid complex (ABLC; 5 mg/kg per day IV) )
Ulinastatin Clinical Studies
Safety & Efficacy of Ulinastatin in Severe Sepsis Patients
Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive care medicine. 2014 Jun;40(6):830-8.
The study concluded that ulinastatin was effective in significantly reducing the mortality, new onset organ dysfunction & duration of hospitalization in Severe Sepsis patients
Ulinastatin Clinical Studies
Safety & Efficacy of Ulinastatin in Severe Acute Pancreatitis Patients
Abraham P, Rodriques J, Moulick N, Dharap S, Chafekar N, Verma PK, Agrawal A, Prabhakar B, Basavaraj A, Shah A, Chaphekar AP, Biswal UC, Malhan ST, Bakshi G. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India. 2013 Aug;61(8):535-8. PMID: 24818336.
The study concluded that ulinastatin was effective in significantly reducing the mortality, new onset organ dysfunction in Severe Acute Pancreatitis patients